Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure-Current Evidence in Special Populations

Overview

Journal Life (Basel)

Specialty Biology

Date 2023 Jun 28

PMID 37374037

Authors

Gassan Moady

Tuvia Ben Gal

Shaul Atar

Affiliations

Soon will be listed here.

Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally used for diabetes mellitus, are gaining more popularity for other indications, owing to their positive cardiovascular and renal effects. SGLT2 inhibitors reduce heart failure (HF) hospitalization and improve cardiovascular outcomes in patients with type 2 diabetes. Later, SGLT2 inhibitors were evaluated in patients with HF with reduced ejection fraction (HFREF) and had beneficial effects independent of the presence of diabetes. Recently, reductions in cardiovascular outcomes were also observed in patients with HF with preserved ejection fraction (HFPEF). SGLT2 inhibitors also reduced renal outcomes in patients with chronic kidney disease. Overall, these drugs have an excellent safety profile with a negligible risk of genitourinary tract infections and ketoacidosis. In this review, we discuss the current data on SGLT2 inhibitors in special populations, including patients with acute myocardial infarction, acute HF, right ventricular (RV) failure, left ventricular assist device (LVAD), and type 1 diabetes. We also discuss the potential mechanisms behind the cardiovascular benefits of these medications.

Citing Articles

Beyond the Benefits: A Case Study on the Complications of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (Euglycemic Diabetic Ketoacidosis (DKA) and Takotsubo Cardiomyopathy).

Sabanci R, Saaed M, Bandi A, Das K, Wilcox M Cureus. 2024; 16(2):e55068.

PMID: 38550506 PMC: 10977859. DOI: 10.7759/cureus.55068.

Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review.

Elian V, Popovici V, Karampelas O, Gradisteanu Pircalabioru G, Radulian G, Musat M Int J Mol Sci. 2024; 25(4).

PMID: 38396657 PMC: 10888162. DOI: 10.3390/ijms25041972.

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure.

Xanthopoulos A, Katsiadas N, Skoularigkis S, Magouliotis D, Skopeliti N, Patsilinakos S Life (Basel). 2023; 13(8).

PMID: 37629635 PMC: 10455594. DOI: 10.3390/life13081778.

References

Fang J, Ewald G, Allen L, Butler J, Westlake Canary C, Colvin-Adams M . Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail. 2015; 21(6):519-34. DOI: 10.1016/j.cardfail.2015.04.013. View

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

Dhingra N, Mistry N, Puar P, Verma R, Anker S, Mazer C . SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Heart Fail. 2021; 8(6):4693-4700. PMC: 8712921. DOI: 10.1002/ehf2.13645. View

Sano M, Goto S . Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation. 2019; 139(17):1985-1987. DOI: 10.1161/CIRCULATIONAHA.118.038881. View

Dave C, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E . Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med. 2019; 171(4):248-256. PMC: 6989379. DOI: 10.7326/M18-3136. View

Swedberg K, Young J, Anand I, Cheng S, Desai A, Diaz R . Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013; 368(13):1210-9. DOI: 10.1056/NEJMoa1214865. View

Cagliostro M, Hundal P, Ting P, Patel S, Sudarshan S, Thomas J . Safety and effects of SGLT-2 inhibitor use among LVAD patients with type 2 diabetes mellitus. Am Heart J Plus. 2024; 18:100154. PMC: 10978353. DOI: 10.1016/j.ahjo.2022.100154. View

Lega I, Bronskill S, Campitelli M, Guan J, Stall N, Lam K . Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019; 21(11):2394-2404. DOI: 10.1111/dom.13820. View

Nassif M, Windsor S, Tang F, Khariton Y, Husain M, Inzucchi S . Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019; 140(18):1463-1476. DOI: 10.1161/CIRCULATIONAHA.119.042929. View

10.

Suhrs H, Nilsson M, Bove K, Zander M, Prescott E . Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study. PLoS One. 2022; 17(2):e0263481. PMC: 8836314. DOI: 10.1371/journal.pone.0263481. View

11.

Lopaschuk G, Karwi Q, Tian R, Wende A, Abel E . Cardiac Energy Metabolism in Heart Failure. Circ Res. 2021; 128(10):1487-1513. PMC: 8136750. DOI: 10.1161/CIRCRESAHA.121.318241. View

12.

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

13.

Dewanjee S, Vallamkondu J, Kalra R, John A, Reddy P, Kandimalla R . Autophagy in the diabetic heart: A potential pharmacotherapeutic target in diabetic cardiomyopathy. Ageing Res Rev. 2021; 68:101338. DOI: 10.1016/j.arr.2021.101338. View

14.

Garg S, Henry R, Banks P, Buse J, Davies M, Fulcher G . Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017; 377(24):2337-2348. DOI: 10.1056/NEJMoa1708337. View

15.

Camci S, Yilmaz E . Effects of Sodium-Glucose Co-Transporter-2 Inhibition on Pulmonary Arterial Stiffness and Right Ventricular Function in Heart Failure with Reduced Ejection Fraction. Medicina (Kaunas). 2022; 58(8). PMC: 9415977. DOI: 10.3390/medicina58081128. View

16.

Gibb A, Hill B . Metabolic Coordination of Physiological and Pathological Cardiac Remodeling. Circ Res. 2018; 123(1):107-128. PMC: 6023588. DOI: 10.1161/CIRCRESAHA.118.312017. View

17.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

18.

Sano M . A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018; 71(5):471-476. DOI: 10.1016/j.jjcc.2017.12.004. View

19.

Salah H, AlAref S, Khan M, Al-Hawwas M, Vallurupalli S, Mehta J . Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022; 21(1):20. PMC: 8817537. DOI: 10.1186/s12933-022-01455-2. View

20.

Kayano H, Koba S, Hirano T, Matsui T, Fukuoka H, Tsuijita H . Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients　- A Randomized Controlled Trial. Circ J. 2020; 84(10):1807-1817. DOI: 10.1253/circj.CJ-20-0341. View